Literature DB >> 7584927

Framingham study insights into hypertensive risk of cardiovascular disease.

W B Kannel1.   

Abstract

Elevated blood pressure is a common and powerful predisposing factor for stroke, coronary disease, cardiac failure and peripheral artery disease imposing a 2-3 fold increased risk of one or more of these atherosclerotic sequelae. The risk ratio imposed by hypertension is greatest for cardiac failure and stroke, but in Western countries coronary disease is the most common and lethal hazard. In hypertensive men and women respectively, 35% and 45% of myocardial infarctions are silent or unrecognized necessitating routine periodic ECG examination for its detection. Comparison of the impacts of systolic and diastolic blood pressure gives no indication of a greater impact of diastolic pressure and isolated systolic hypertension is distinctly hazardous. Over-reliance on diastolic pressure to assess risk can be misleading, particularly in advanced age. Attributable risk estimates suggest that 78% of hypertension in men and 65% in women is directly attributable to adiposity, making weight control of paramount importance for primary prevention of hypertension. The likelihood of development of cardiovascular disease in the hypertensive patient is greatly enhanced by the presence of metabolically-linked risk factors and already existent cardiovascular conditions. These influence the urgency and choice of therapy. Rational and efficient assessment of the hypertensive candidate for cardiovascular disease requires use of a cardiovascular risk profile evaluating the joint effect of multiple risk factors and effective treatment improves multivariate risk.

Entities:  

Mesh:

Year:  1995        PMID: 7584927     DOI: 10.1291/hypres.18.181

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  24 in total

1.  Estrogen depletion differentially affects blood pressure depending on age in Long-Evans rats.

Authors:  John T Clark; Munmun Chakraborty-Chatterjee; Milton Hamblin; J Michael Wyss; Ian H Fentie
Journal:  Endocrine       Date:  2004-11       Impact factor: 3.633

Review 2.  Hypertension, hypertrophy, heart failure.

Authors:  M G Nicholls
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

3.  Pseudobulbar paralysis in the Renaissance: Cosimo I de' Medici case.

Authors:  F Arba; D Inzitari; D Lippi
Journal:  Neurol Sci       Date:  2014-03-07       Impact factor: 3.307

Review 4.  The role of olmesartan medoxomil in the management of hypertension.

Authors:  Thomas Unger; Gordon T McInnes; Joel M Neutel; Michael Böhm
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 5.  Effects of hormone replacement therapy on the sympathetic nervous system and blood pressure.

Authors:  J Michael Wyss; Scott H Carlson
Journal:  Curr Hypertens Rep       Date:  2003-06       Impact factor: 5.369

Review 6.  Hypertension: reflections on risks and prognostication.

Authors:  William B Kannel
Journal:  Med Clin North Am       Date:  2009-05       Impact factor: 5.456

7.  Trends of hypertension prevalence, awareness, treatment and control in rural areas of northern China during 1991-2011.

Authors:  J Wang; X Ning; L Yang; H Lu; J Tu; W Jin; W Zhang; T-C Su
Journal:  J Hum Hypertens       Date:  2013-06-06       Impact factor: 3.012

Review 8.  Managing the hypertensive patient with ischemic heart disease.

Authors:  Clive Rosendorff
Journal:  Curr Hypertens Rep       Date:  2002-10       Impact factor: 5.369

9.  Dietary sodium and potassium intake is not associated with elevated blood pressure in US adults with no prior history of hypertension.

Authors:  Shailendra Sharma; Kim McFann; Michel Chonchol; Jessica Kendrick
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-04-11       Impact factor: 3.738

10.  Combined Cardiac Risk Factors Predict COVID-19 Related Mortality and the Need for Mechanical Ventilation in Coptic Clergy.

Authors:  Michael Y Henein; Ibadete Bytyçi; Rachel Nicoll; Rafik Shenouda; Sherif Ayad; Matteo Cameli; Federico Vancheri
Journal:  J Clin Med       Date:  2021-05-12       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.